Mutations in PRKCSH Cause Isolated Autosomal Dominant Polycystic Liver Disease
Open accessThe DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.
Abstract
Autosomal dominant polycystic liver disease (ADPLD) is a distinct clinical and genetic entity that can occur independently from autosomal dominant polycystic kidney disease (ADPKD). We previously studied two large kindreds and reported localization of a gene for ADPLD to an approximately 8-Mb region, flanked by markers D19S586/D19S583 and D19S593/D19S579, on chromosome 19p13.2-13.1. Expansion of these kindreds and identification of an additional family allowed us to define flanking markers CA267 and CA048 in an approximately 3-Mb region containing >70 candidate genes. We used a combination of denaturing high-performance liquid chromatography (DHPLC) heteroduplex analysis and direct sequencing to screen a panel of 15 unrelated affected individuals for mutations in genes from this interval. We found sequence variations in a known gene, PRKCSH, that were not observed in control individuals, that segregated with the disease haplotype, and that were predicted to be chain-terminating mutations. In contrast to PKD1, PKD2, and PKHD1, PRKCSH encodes a previously described human protein termed "protein kinase C substrate 80K-H" or "noncatalytic beta-subunit of glucosidase II." This protein is highly conserved, is expressed in all tissues tested, and contains a leader sequence, an LDLa domain, two EF-hand domains, and a conserved C-terminal HDEL sequence. Its function may be dependent on calcium binding, and its putative actions include the regulation of N-glycosylation of proteins and signal transduction via fibroblast growth-factor receptor. In light of the focal nature of liver cysts in ADPLD, the apparent loss-of-function mutations in PRKCSH, and the two-hit mechanism operational in dominant polycystic kidney disease, ADPLD may also occur by a two-hit mechanism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, Glucosidase II is involved in human polycystic disease [8,9,10] and finally in the demyelinating ones of the central nervous system (CNS), according to the latest evidence [11].”
From GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review (2022) · cites this paper as [9]
Citations
Cites
Setting the Standards: Quality Control in the Secretory Pathway
Ellgaard, L., Molinari, M., & Helenius, A. (1999) · Science · doi:10.1126/science.286.5446.1882 · Cited by 1,192
Harris, P. C., & Torres, V. E. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.101707.125712 · Cited by 801
Self-citationSomatic Inactivation of Pkd2 Results in Polycystic Kidney Disease
Wu, G., D'Agati, V., Cai, Y., Markowitz, G., Park, J. H., Reynolds, D. M., Maeda, Y., Le, T. C., Hou, H., Kucherlapati, R., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81570-6 · Cited by 570 · cited 2×
“The latter region was excluded from mutation detection, because we hypothesized that—as is the case with ADPKD (Wu et al. 1998)—the liver cystic pathway in ADPLD will be conserved in mice.”
BackgroundSelf-citationRavine, D., Sheffield, L., Danks, D. M., Gibson, R. N., Walker, R. G., & Kincaid-Smith, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92026-5 · Cited by 564 · cited 11×
“The latter region was excluded from mutation detection, because we hypothesized that—as is the case with ADPKD (Wu et al. 1998)—the liver cystic pathway in ADPLD will be conserved in mice.”
BackgroundInfluentialPazour, G. J., San Agustin, J. T., Follit, J. A., Rosenbaum, J. L., & Witman, G. B. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00877-1 · Cited by 531 · cited 2×
“1999) and only selectively trafficked to the primary cilia (Pazour et al. 2002).”
BackgroundOnuchic, L. F., Furu, L., Nagasawa, Y., Hou, X., Eggermann, T., Ren, Z., Bergmann, C., Senderek, J., Esquivel, E., Zeltner, R., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/340448 · Cited by 508 · cited 1×
“A 386-bp RT-PCR product from exons 10–13 of PRKCSH was 32P-labeled using the multiprime method and was hybridized to an adult human MTN blot (Clontech), as described elsewhere (Onuchic et al. 2002).”
MethodSelf-citationNiehues, R., Hasilik, M., Alton, G., Körner, C., Schiebe-Sukumar, M., Koch, H. G., Zimmer, K. P., Wu, R., Harms, E., Reiter, K., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2350 · Cited by 422 · cited 2×
“Interestingly, autosomal recessive carbohydratedeficient glycoprotein syndrome type Ib is associated with congenital hepatic fibrosis and results from nearly complete absence of phosphomannose isomerase, the enzyme needed to maintain the dolichol pyrophosphateoligosaccharide pool (Jaeken et al. 1998; Niehues et al. 19…”
BackgroundThornalley, P. J. (1998) · PubMed · Cited by 387
Identification and Characterization of Polycystin-2, thePKD2 Gene Product
Cai, Y., Maeda, Y., Cedzich, A., Torres, V. E., Wu, G., Hayashi, T., Mochizuki, T., Park, J. H., Witzgall, R., & Somlo, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.40.28557 · Cited by 364 · cited 1×
“It has been suggested that the polycystin-1/2 complex forms in the ER (Newby et al. 2002) and polycystin-2 is largely retained in the ER membrane (Cai et al. 1999) and only selectively trafficked to the primary cilia (Pazour et al. 2002).”
BackgroundSelf-citationLi, Y. M., Mitsuhashi, T., Wojciechowicz, D., Shimizu, N., Li, J., Stitt, A., He, C., Banerjee, D., & Vlassara, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11047 · Cited by 341 · cited 2×
“Although 80K-H turned out to be a poor substrate for PKC, other possible functions were later suggested by its ability to bind advanced glycation end products (Li et al. 1996; Thornalley 1998) and by its rapid phosphorylation following activation of fibroblast growth-factor receptors (Shaoul et al.”
Background
Cited by
Roles of N-Linked Glycans in the Endoplasmic Reticulum
Helenius, A., & Aebi, M. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073752 · Cited by 2,037
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
Self-citationBergmann, C., Guay-Woodford, L. M., Harris, P. C., Horie, S., Peters, D. J. M., & Torres, V. E. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0047-y · Cited by 807
Self-citationPorath, B., Gainullin, V. G., Cornec-Le Gall, E., Dillinger, E. K., Heyer, C. M., Hopp, K., Edwards, M. E., Madsen, C. D., Mauritz, S. R., Banks, C. J., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.05.004 · Cited by 475
Self-citationGenetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases
Cornec-Le Gall, E., Torres, V. E., & Harris, P. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017050483 · Cited by 406
Self-citationHogan, M. C., Masyuk, T. V., Page, L. J., Kubly, V. J., Bergstralh, E. J., Li, X., Kim, B., King, B. F., Glockner, J., Holmes, D. R., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121291 · Cited by 333
Self-citationPolycystin-2 traffics to cilia independently of polycystin-1 by using an N-terminal RVxP motif
Geng, L., Okuhara, D., Yu, Z., Tian, X., Cai, Y., Shibazaki, S., & Somlo, S. (2006) · Journal of Cell Science · doi:10.1242/jcs.02818 · Cited by 282
“Mutations in the genes encoding the subunit of the glucosidase II enzyme (Li et al., 2003; Drenth et al., 2003) or the SEC63 component of the protein translocon (Davila et al., 2004) lead to bile duct cysts histopathologically indistinguishable from those seen in ADPKD.”
BackgroundSelf-citationMutations in SEC63 cause autosomal dominant polycystic liver disease
Davila, S., Furu, L., Gharavi, A. G., Tian, X., Onoe, T., Qian, Q., Li, A., Cai, Y., Kamath, P. S., King, B. F., et al. (2004) · Nature Genetics · doi:10.1038/ng1357 · Cited by 286
Self-citationMasyuk, T. V., Masyuk, A. I., Torres, V. E., Harris, P. C., & Larusso, N. F. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.039 · Cited by 283
“At the end of each treatent period, 12 rats were killed and the following paameters were assessed: (1) body weight, (2) serum biohemistry, (3) liver and kidney weights, (4) cAMP levels in ile ducts and serum, (5) cystic volumes in liver and idneys, and (6) hepatic and renal fibrosis.”
MethodSelf-citationFedeles, S. V., Tian, X., Gallagher, A.-R., Mitobe, M., Nishio, S., Lee, S. H., Cai, Y., Geng, L., Crews, C. M., & Somlo, S. (2011) · Nature Genetics · doi:10.1038/ng.860 · Cited by 262
Self-citationCongenital disorders of glycosylation
Chang, I. J., He, M., & Lam, C. T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.45 · Cited by 235
Liver and kidney disease in ciliopathies
Gunay‐Aygun, M. (2009) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30225 · Cited by 237
“(ADPKD MRI is from Heptinstall’s pathology of the kidney, Ed: Jennette J., Olson J., Schwartz M., Silva F.) et al., 2003; Li et al., 2003; Tahvanainen et al., 2003; Davila et al., 2004; Waanders et al., 2006].”
BackgroundMasyuk, T. V., Huang, B. Q., Ward, C. J., Masyuk, A. I., Yuan, D., Splinter, P. L., Punyashthiti, R., Ritman, E. L., Torres, V. E., Harris, P. C., et al. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.09.001 · Cited by 209
Self-citationIsolated polycystic liver disease genes define effectors of polycystin-1 function
Besse, W., Dong, K., Choi, J., Punia, S., Fedeles, S. V., Choi, M., Gallagher, A.-R., Huang, E. B., Gulati, A., Knight, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90129 · Cited by 203
Self-citationPolycystic liver disease: an overview of pathogenesis, clinical manifestations and management
Cnossen, W. R., & Drenth, J. P. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-9-69 · Cited by 200
“Genetic analyses of both PCLD genes PRKCSH [OMIM*177060] and SEC63 [OMIM*608648] may confirm the clinical diagnosis and differentiate it from other PLD (Table 1) [56-58].”
BackgroundEvaluation of hepatic cystic lesions
Lantinga, M. A. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i23.3543 · Cited by 198
Trombetta, E. S. (2003) · Glycobiology · doi:10.1093/glycob/cwg075 · Cited by 191
“Mutations in the b-subunit of glucosidase II are associated with autosomal dominant plycystic liver disease (Drenth et al., 2003; Li et al., 2003).”
BackgroundAnimal models of biliary injury and altered bile acid metabolism
Mariotti, V., Strazzabosco, M., Fabris, L., & Calvisi, D. F. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.027 · Cited by 176
“The two known disease causative genes for ADPLD are PRKCSH and SEC63, which encode for non-cilial, ER-localized proteins involved in protein biogenesis and posttranslational modifications[92-94].”
A polycystin-centric view of cyst formation and disease: the polycystins revisited
Ong, A. C. M., & Harris, P. C. (2015) · Kidney International · doi:10.1038/ki.2015.207 · Cited by 176
“In PCLD, the disease proteins are involved in glycosylation or translocation of membrane proteins into the ER, plus ER quality control 69, 70 and hence, involved with processing the large and complex PC1 or PC2.”
Senum, S. R., Li, Y. (. M., Benson, K. A., Joli, G., Olinger, E., Lavu, S., Madsen, C. D., Gregory, A. V., Neatu, R., Kline, T. L., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.11.016 · Cited by 174
Self-citationUDP-GlC:glycoprotein glucosyltransferase-glucosidase II, the ying-yang of the ER quality control
D’Alessio, C., Caramelo, J. J., & Parodi, A. J. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.12.014 · Cited by 167
“been object of growing interest in the last years, as autosomal dominant polycystic liver disease may develop in individuals carrying mutations in the GIIβ gene [64-66].”
BackgroundMolecular diagnostics for autosomal dominant polycystic kidney disease
Harris, P. C., & Rossetti, S. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.18 · Cited by 166
“In individuals with severe polycystic liver disease and a few renal cysts, phenotypic overlap exists with autosomal dominant polycystic liver disease, which is caused by mutations in PRKCSH or SEC63”
BackgroundALG9 Mutation Carriers Develop Kidney and Liver Cysts
Besse, W., Chang, A. R., Luo, J. Z., Triffo, W. J., Moore, B. S., Gulati, A., Hartzel, D. N., Mane, S., Regeneron Genetics Center, Torres, V. E., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019030298 · Cited by 158
Self-citationBiliary differentiation and bile duct morphogenesis in development and disease
Raynaud, P., Carpentier, R., Antoniou, A., & Lemaigre, F. P. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.07.020 · Cited by 158
Lang, S., Benedix, J., Fedeles, S. V., Schorr, S., Schirra, C., Schäuble, N., Jalal, C., Greiner, M., Haßdenteufel, S., Tatzelt, J., et al. (2012) · Journal of Cell Science · doi:10.1242/jcs.096727 · Cited by 155
“On the genetic level, ADPLD is heterogeneous involving at least two different genes: PRKCSH, encoding the b-subunit of glucosidase II, and SEC63 (Drenth et al., 2003; Li et al., 2003; Davila et al., 2004).”
BackgroundSelf-citationVan Keimpema, L., De Koning, D. B., Van Hoek, B., Van Den Berg, A. P., Van Oijen, M. G. H., De Man, R. A., Nevens, F., & Drenth, J. P. H. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02247.x · Cited by 152
“Occurrence of complications 6 (10) 33 (51) Cyst haemorrhage 5 (8) 15 (20)”
Loss of Oriented Cell Division Does not Initiate Cyst Formation
Nishio, S., Tian, X., Gallagher, A. R., Yu, Z., Patel, V., Igarashi, P., & Somlo, S. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060603 · Cited by 137
Self-citationPolycystin-1: A master regulator of intersecting cystic pathways
Fedeles, S. V., Gallagher, A.-R., & Somlo, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.01.004 · Cited by 130
Self-citationGeller, D. S., Zhang, J., Zennaro, M.-C., Vallo-Boado, A., Rodriguez-Soriano, J., Furu, L., Haws, R., Metzger, D., Botelho, B., Karaviti, L., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005111188 · Cited by 131
Self-citationKirchner, G. I., Rifai, K., Cantz, T., Nashan, B., Terkamp, C., Becker, T., Strassburg, C. P., Barg‐Hock, H., Wagner, S., Lück, R., et al. (2006) · Liver Transplantation · doi:10.1002/lt.20780 · Cited by 117
Devuyst, O., Ahn, C., Barten, T. R. M., Brosnahan, G., Cadnapaphornchai, M. A., Chapman, A. B., Gall, É. C.-L., Drenth, J. P. H., Gansevoort, R. T., Harris, P. C., et al. (2025) · Kidney International · doi:10.1016/j.kint.2024.07.009 · Cited by 179
Self-citationWei, W., Hackmann, K., Xu, H., Germino, G., & Qian, F. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703218200 · Cited by 115
New Advances in Evaluation and Management of Patients with Polycystic Liver Disease
Arnold, H. L., & Harrison, S. A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00263.x · Cited by 115
Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases
Fabris, L., Fiorotto, R., Spirlì, C., Cadamuro, M., Mariotti, V., Perugorria, M. J., Bañales, J. M., & Strazzabosco, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0156-4 · Cited by 127
Masyuk, T. V., Huang, B. Q., Masyuk, A. I., Ritman, E. L., Torres, V. E., Wang, X., Harris, P. C., & LaRusso, N. F. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63427-x · Cited by 118
Self-citationTranslational research in ADPKD: lessons from animal models
Happé, H., & Peters, D. J. M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.137 · Cited by 116
Gradilone, S. A., Masyuk, T. V., Huang, B. Q., Banales, J. M., Lehmann, G. L., Radtke, B. N., Stroope, A., Masyuk, A. I., Splinter, P. L., & LaRusso, N. F. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.010 · Cited by 97
Molecular mechanisms of bile duct development
Zong, Y., & Stanger, B. Z. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.06.020 · Cited by 95
“Another kind of PLD, called autosomal dominant polycystic liver disease (ADPLD), is not associated with any renal diseases and is associated with mutations in the PRKCSH and SEC63 genes (Davila et al., 2004; Drenth et al., 2003; Li et al., 2003).”
BackgroundDiagnosis and Screening of Autosomal Dominant Polycystic Kidney Disease
Pei, Y., & Watnick, T. J. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2009.12.001 · Cited by 98
Polycystic liver diseases: advanced insights into the molecular mechanisms
Perugorria, M. J., Masyuk, T. V., Marín, J. J. G., Marzioni, M., Bujanda, L., LaRusso, N. F., & Bañales, J. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.155 · Cited by 103
Identification of potential synthetic lethal genes to p53 using a computational biology approach
Wang, X., & Simon, R. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-30 · Cited by 91
“PRKCSH protein kinase C substrate 80K-H roles in inflammation, cell growth, signaling and death [32]”
BackgroundGlycoprotein folding and quality-control mechanisms in protein-folding diseases
Ferris, S., Kodali, V., & Kaufman, R. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.014589 · Cited by 98
“…channel that undergoes inefficient folding and anterograde transport, and dislocates from the ER to form cytoplasmic, juxtanuclear aggresomes that are cleared by proteasomal degradation, as well as autophagy (Kopito, 2000; Farinha and Amaral, 2005; Fu and Sztul, 2009; Luciani et al., 2010).”
BackgroundCnossen, W. R., te Morsche, R. H. M., Hoischen, A., Gilissen, C., Chrispijn, M., Venselaar, H., Mehdi, S., Bergmann, C., Veltman, J. A., & Drenth, J. P. H. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309438111 · Cited by 90
Determinants of Renal Disease Variability in ADPKD
Harris, P. C., & Rossetti, S. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2009.12.004 · Cited by 91
Polycystic liver disease is a disorder of cotranslational protein processing
Drenth, J. P. H., Martina, J. A., KERKHOF, R., Bonifacino, J. S., & Jansen, J. B. �. �. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.11.004 · Cited by 87
Hepatorenal findings in obligate heterozygotes for autosomal recessive polycystic kidney disease
Gunay‐Aygun, M., Turkbey, B. I., Bryant, J. C., Daryanani, K., Gerstein, M. T., Piwnica–Worms, K., Choyke, P. L., Heller, T., & Gahl, W. A. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.09.001 · Cited by 78
TRPP2 and autosomal dominant polycystic kidney disease
Köttgen, M. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2007.01.003 · Cited by 80
“Although the physiological relevance of TRPP2 channel function in the ER remains to be clarified, the existence of other ER-resident “cystoproteins” like bcl-2 [113], PRKCSH (glucosidase II β subunit) [114] or SEC63 [115] points to a potential role of the ER in cystogenesis.”
BackgroundPolycystic liver disease: a clinical review
Chandok, N. (2012) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31406-1 · Cited by 83
Cilia and polycystic kidney disease
Ma, M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.05.003 · Cited by 78
Isolated Polycystic Liver Disease
Qian, Q. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2009.12.005 · Cited by 67
“SEC63 is located on the long arm of chromosome 6 (6q21-q23)(6).”
BackgroundInfluentialSelf-citationExtensive mutational analysis ofPRKCSH andSEC63 broadens the spectrum of polycystic liver disease
Waanders, E., te Morsche, R. H. M., de Man, R. A., Jansen, J. B. M. J., & Drenth, J. P. H. (2006) · Human Mutation · doi:10.1002/humu.9441 · Cited by 64
“%) with PRKCSH [Li et al., 2003] and 8 patients (12”
BackgroundComplementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation
Vogt, G., Bustamante, J. C., Chapgier, A. L. A., Feinberg, J. M., Boisson‐Dupuis, S., Pïcard, C., Mahlaoui, N., Gineau, L., Alcaïs, A., Lamaze, C., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071987 · Cited by 70
Sec63 and Xbp1 regulate IRE1α activity and polycystic disease severity
Fedeles, S. V., So, J., Shrikhande, A., Lee, S. H., Gallagher, A., Barkauskas, C. E., Somlo, S., & Lee, A.-H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78863 · Cited by 72
Self-citationDrenth, J. P. H., Martina, J. A., Morsche, R. H. M. T., Jansen, J. B. �. �., & Bonifacino, J. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.023 · Cited by 62
Current management of noninfectious hepatic cystic lesions: A review of the literature
Macedo, F. I. (2013) · World Journal of Hepatology · doi:10.4254/wjh.v5.i9.462 · Cited by 66
Polycystic disease of the liver
Everson, G. T., Taylor, M. R. G., & Doctor, B. R. (2004) · Hepatology · doi:10.1002/hep.1840400404 · Cited by 185
Wilkinson, B. M., Purswani, J., & Stirling, C. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m510455200 · Cited by 61
Igarashi, P., & Somlo, S. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007030299 · Cited by 56
Self-citationPolycystic liver and kidney diseases
Tahvanainen, E., Tahvanainen, P., Kääriäinen, H., & Höckerstedt, K. (2005) · Annals of Medicine · doi:10.1080/07853890500389181 · Cited by 56
“Two independent groups found the first PCLD gene in 2003 (43,44) and the second gene was found very rapidly after that (45) (Table I), but because mutations in these genes have not been found in all families, there probably still exist undiscovered gene(s) causing PCLD.”
BackgroundCongenital disorders of glycosylation in hepatology: The example of polycystic liver disease
Janssen, M. J., Waanders, E., Woudenberg, J., Lefeber, D. J., & Drenth, J. P. H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.011 · Cited by 54
“Protein Kinase C Substrate 80K-H (PRKCSH) was identified in 2003 as the first causative gene for PCLD [14,15], while one year later SEC63 mutations were found in different families [16].”
BackgroundGao, H., Wang, Y., Wegierski, T., Skouloudaki, K., Pütz, M., Fu, X., Engel, C., Boehlke, C., Peng, H., Kuehn, E. W., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddp463 · Cited by 52
Drenth, J. P. H., Tahvanainen, E., Morsche, R. H. M. T., Tahvanainen, P., Kääriäinen, H., Höckerstedt, K., van de Kamp, J. M., Breuning, M. H., & Jansen, J. B. �. �. (2004) · Hepatology · doi:10.1002/hep.20141 · Cited by 52
“(11) Note that the first 4 bases immediately after exon 16 read GTGA, so either deletion of GT (IVS16_1delGT) or TG (1437 2delTG) will result in a similar sequence on the electrospherogram (GA).”
BackgroundYaguchi, H., Okumura, F., Takahashi, H., Kano, T., Kameda, H., Uchigashima, M., Tanaka, S., Watanabe, M., Sasaki, H., & Hatakeyama, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.307678 · Cited by 54
“Moreover, it has been reported that 80K-H is one of the genes responsible for autosomal dominant polycystic liver disease (24, 25).”
BackgroundJanssen, M. J., Waanders, E., Morsche, R. H. M. T., Xing, R., Dijkman, H. B. P. M., Woudenberg, J., & Drenth, J. P. H. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.004 · Cited by 65
Molecular pathogenesis of autosomal dominant polycystic kidney disease
Yoder, B. K., Mulroy, S., Eustace, H., Boucher, C. A., & Sandford, R. N. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406010362 · Cited by 58
Pathogenesis of ductal plate malformation
Desmet, V. J. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03702.x · Cited by 48
Mantovani, V., Bin, S., Graziano, C., Capelli, I., Minardi, R., Aiello, V., Ambrosini, E., Cristalli, C. P., Mattiaccio, A., Pariali, M., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00464 · Cited by 49
“(Tyr423), was already reported in a family with autosomal dominant polycystic liver disease (Li et al., 2003).”
BackgroundA novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria
Francis, J. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh426 · Cited by 47
“Using denaturing high-performance liquid chromatography (DHPLC) as described previously [ 6 ], we did not observe this allele in any other individuals (data not shown), indicating that the G304K mutation is not a common polymorphism.”
MethodNew treatments for autosomal dominant polycystic kidney disease
Chang, M., & Ong, A. C. M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12136 · Cited by 49
Kawaai, K., Hisatsune, C., Kuroda, Y., Mizutani, A., Tashiro, T., & Mikoshiba, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805828200 · Cited by 46
N-Glycosylation Determines the Abundance of the Transient Receptor Potential Channel TRPP2
Hofherr, A., Wagner, C. J., Fedeles, S. V., Somlo, S., & Köttgen, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.562264 · Cited by 54
Self-citationRegulation of polycystin expression, maturation and trafficking
Hu, J., & Harris, P. C. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109630 · Cited by 51
Physiologic mechanisms underlying polycystic kidney disease
Boletta, A., & Caplan, M. J. (2025) · Physiological Reviews · doi:10.1152/physrev.00018.2024 · Cited by 57
Waanders, E., Venselaar, H., Morsche, R. T., Koning, D. D., Kamath, P. S., Torres, V., Somlo, S., & Drenth, J. P. H. (2010) · Clinical Genetics · doi:10.1111/j.1399-0004.2009.01353.x · Cited by 49
“In all, mutations of either PRKCSH or SEC63 gene account for approximately 25% of PCLD cases, indicating the existence of at least one more locus for PCLD (7, 8, 10, 13).”
BackgroundSelf-citationPRKCSH contributes to tumorigenesis by selective boosting of IRE1 signaling pathway
Shin, G., Moon, S. U., Kang, H. S., Choi, H., Han, H. D., & Kim, K. (2019) · Nature Communications · doi:10.1038/s41467-019-11019-w · Cited by 47
Trombetta, E. S., & Parodi, A. J. (2005) · Methods · doi:10.1016/j.ymeth.2004.10.004 · Cited by 49
Management of polycystic liver disease
Everson, G. T., & Taylor, M. R. G. (2005) · Current Gastroenterology Reports · doi:10.1007/s11894-005-0061-6 · Cited by 43
Treatment of Polycystic Liver Disease: One Size Does Not Fit All
Torres, V. E. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.04.009 · Cited by 41
Self-citationHogan, M. C., Chamberlin, J. A., Vaughan, L. E., Waits, A. L., Banks, C. J., Leistikow, K., Oftsie, T., Madsen, C. D., Edwards, M. E., Glockner, J. F., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13661119 · Cited by 48
Self-citationDevelopmental abnormalities and liver disease in childhood
Portmann, B. C., & Roberts, E. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00003-9 · Cited by 40
“This protein now renamed hepatocystin, seems to segregate in families with PCLD.(630,631) The protein is widely distributed in tissues and predicted to be an endoplasmic reticulum luminal protein that recycles from the Golgi.”
BackgroundResultPolycystic liver disease: New insights into disease pathogenesis
Masyuk, T. V., & LaRusso, N. F. (2006) · Hepatology · doi:10.1002/hep.21199 · Cited by 38
“Recent advances have suggested that abnormalities in at least three clearly distinguishable cellular events occur: (1) cell proliferation, apoptosis and differentiation; (2) cell-matrix interactions; and (3) fluid secretion.”
BackgroundGenetic Spectrum of Polycystic Kidney and Liver Diseases and the Resulting Phenotypes
Yang, H., Sieben, C. J., Schauer, R. S., & Harris, P. C. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.04.004 · Cited by 39
Down-regulating Circular RNA Prkcsh suppresses the inflammatory response after spinal cord injury
Ning, B., Chen, J., Zhang, Y.-N., Tian, L., Zhang, Y., & Li, X.-Y. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.314114 · Cited by 34
“It has also been reported that PRKCSH contributes to tumorigenesis by alternatively stimulating inositol-requiring enzyme 1 signaling (Shin et al., 2019).”
BackgroundGenetics of polycystic liver diseases
Lee, P. Y., van de Laarschot, L. F. M., Bañales, J. M., & Drenth, J. P. H. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000514 · Cited by 38
The ciliary impact of nonciliary gene mutations
Lovera-Ulecía, M., & Lüders, J. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.06.001 · Cited by 36
Genetics, pathobiology and therapeutic opportunities of polycystic liver disease
Olaizola, P., Rodrigues, P. M., Caballero-Camino, F. J., Izquierdo‐Sánchez, L., Aspichueta, P., Bujanda, L., LaRusso, N. F., Drenth, J. P. H., Perugorria, M. J., & Bañales, J. M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00617-7 · Cited by 41
Polycystin-1 Negatively Regulates Polycystin-2 Expression via the Aggresome/Autophagosome Pathway
Cebotaru, V., Cebotaru, L., Kim, H., Chiaravalli, M., Boletta, A., Qian, F., & Guggino, W. B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.501205 · Cited by 35
“Mutations in the PRKCSH gene lead to autosomal dominant polycystic liver disease (18, 19).”
BackgroundCoquillard, C. L., Berger, J., Daily, M. F., Shah, M. B., Mei, X., Martí, F., & Gedaly, R. (2015) · Liver International · doi:10.1111/liv.13041 · Cited by 32
“It co-occurs with PKD in the majority of cases, although PLD can occur on its own with autosomal dominant inheritance (5).”
BackgroundDiagnostic Imaging of Autosomal Dominant Polycystic Kidney Disease
Gradzik, M., Niemczyk, M., Gołębiowski, M., & Pączek, L. (2015) · Polish Journal of Radiology · doi:10.12659/pjr.894482 · Cited by 31
Loss of Heterozygosity Is Present in SEC63 Germline Carriers with Polycystic Liver Disease
Janssen, M. J., Salomon, J., Morsche, R. H. M. T., & Drenth, J. P. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050324 · Cited by 36
“So far two genes, PRKCSH (MIM# 177060) [2,3] and SEC63 (MIM# 608648) [4], have been associated with the development of PCLD.”
BackgroundGlucosidase II and MRH-Domain Containing Proteins in the Secretory Pathway
D’Alessio, C., & Dahms, N. M. (2015) · Current Protein and Peptide Science · doi:10.2174/1389203716666150213160438 · Cited by 34
Knisely, A. S. (2003) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.20479 · Cited by 30
Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county
Suwabe, T., Chamberlain, A. M., Killian, J. M., King, B. F., Gregory, A., Madsen, C. D., Wang, X., Kline, T. L., Chebib, F. T., Hogan, M. C., et al. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100166 · Cited by 29
Self-citationPolycystic Liver Disease: Pathophysiology, Diagnosis and Treatment
Norcia, L. F., Watanabe, E. M., Filho, P. T. H., Hasimoto, C. N., Pelafsky, L., de Oliveira, W. K., & Sassaki, L. Y. (2022) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s377530 · Cited by 38
Advances in management of polycystic liver disease
Everson, G. T., Helmke, S. M., & Doctor, B. R. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.4.563 · Cited by 29
Stokman, M. F., Bijnsdorp, I. V., Schelfhorst, T., Pham, T. V., Piersma, S. R., Knol, J. C., Giles, R. H., Bongers, E. M. H. F., Knoers, N. V. A. M., Liliën, M. R., et al. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.07.008 · Cited by 31
Isolated Polycystic Liver Disease: An Unusual Cause of Recurrent Variceal Bleed
Khan, M. S., Khan, Z. H., Javaid, T., Akhtar, J., Moustafa, A., Lal, A., Tiwari, A., & Taleb, M. (2018) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2018/2902709 · Cited by 27
“1) and encodes for a protein called hepatocystin [4].”
BackgroundHoffrogge, R., Beyer, S., Hübner, R., Mikkat, S., Mix, E., Scharf, C., Schmitz, U., Pauleweit, S., Berth, M., Zubrzycki, I. Z., et al. (2006) · PROTEOMICS · doi:10.1002/pmic.200600614 · Cited by 29
A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family
Besse, W., Choi, J., Ahram, D. F., Mane, S., Sanna‐Cherchi, S., Torres, V. E., & Somlo, S. (2018) · Human Mutation · doi:10.1002/humu.23383 · Cited by 28
“Affected-only analysis was applied because incomplete penetrance PCLD has been reported (Besse et al., 2017; Cnossen et al., 2014; Li et al., 2003; Qian et al., 2003).”
MethodSelf-citationDeficiency of hepatocystin induces autophagy through an mTOR-dependent pathway
Yang, J. H., Zhao, Y., Ma, K., Jiang, F.-J., Liao, W., Zhang, P., Zhou, J., Tu, B., Wang, L., Kampinga, H. H., et al. (2011) · Autophagy · doi:10.4161/auto.7.7.15822 · Cited by 26
Metadata
- Authors
- Li, A., Davila, S., Furu, L., Qian, Q., Tian, X., Kamath, P. S., King, B. F., Torres, V. E., & Somlo, S.
- Affiliations
- Yale University (US)
- Mayo Clinic (US)
- Corresponding author
- Somlo, Stefan
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2003-03
- Volume
- 72
- Issue
- 3
- Pages
- 691-703
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1180260
- OpenAlex
- W2111226757
- Cited by
- 193
- References
- 42
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 8 · 2019: 9 · 2018: 8 · 2017: 7 · 2016: 3 · 2015: 10 · 2014: 13 · 2013: 6 · 2012: 10
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3793 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P50DK057328, T32-DK07356, R01DK051041, P50DK57328, DK51041, T32DK007356)
- National Center for Research Resources (M01-RR00 585, M01RR000585)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Keywords
- autosomal dominant polycystic liver disease, PRKCSH, loss-of-function mutations, two-hit mechanism, haplotype mapping, N-glycosylation, fibroblast growth factor receptor signaling, autosomal dominant polycystic kidney disease
- MeSH terms
- Myristoylated Alanine-Rich C Kinase Substrate, Amino Acid Sequence, Base Sequence, Calcium-Binding Proteins, Chromosome Mapping, Chromosomes, Human, Pair 19, Cysts, DNA, Female, Genes, Dominant, Genetic Markers, Glucosidases, Haplotypes, Humans, Genetic Linkage, Liver Diseases, Male, Membrane Proteins, Molecular Sequence Data, Mutation, Pedigree, Phosphoproteins, Protein Kinase C, Sequence Alignment, Polycystic Kidney, Autosomal Dominant, Point Mutation, Sequence Homology, Amino Acid, Alternative Splicing, Amino Acid Substitution, Reverse Transcriptase Polymerase Chain Reaction, Intracellular Signaling Peptides and Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.